Startups

Paralegal

Lyell Immunopharma · Seattle, Washington, United States; South San Francisco, California, United States · On-site

← All jobs
About Lyell Immunopharma

Lyell is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. Backed by 8VC.

About the role

The Paralegal is responsible for a broad range of legal, corporate, public company reporting and healthcare and corporate compliance duties to support the company’s needs. The Paralegal will deliver confident and proactive support, work collaboratively as well as independently and be comfortable with, and skilled in, interacting with senior management and employees at all levels throughout the company. This role will lead the continuous improvement of legal operations to optimize processes and drive efficiency. Found on 1752vc Careers, the job board for startup and VC roles.

What they're looking for

  • Ability to be both an “architect” and a “plumber” – to see the big picture and to execute it
  • Entrepreneurial spirit and growth mindset
  • Able and willing to take on additional roles and functions to support the law department and company operations
  • Detail-oriented and organized
  • Strong sense of ownership for projects and results and passionate about their work
More about this role

Using living cells to treat – and sometimes even cure – cancer is one of the most dramatic advances in modern medicine. Patients with hematologic malignancies have been successfully treated with cell therapies. However, these profound results have not yet been achieved in patients with solid tumors, representing approximately 90% of all cancers. And for patients with hematologic malignancies, there is a need for next-generation cell therapies that can deliver increased response rates and longer duration of response. We are a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid tumors or hematologic malignancies. Lyell’s product candidates are enhanced with novel technology designed to generate T cells that resist exhaustion and have qualities of durable stemness in order to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical response. We were founded by cell therapy pioneers whose decades of research elevated the broader understanding of T-cell biology and its interaction with cancer. In our quest to advance next-generation CAR T-cell therapies, we have built a fully integrated company capable of...

Read the full posting on Lyell Immunopharma's site ↗

Legal

Build your edge while you search

Free tools for founders and investors, plus VC Unfiltered, our take on startups, venture and the people who build them.